Molecular Partners AG (MOLN)
- Previous Close
3.6500 - Open
3.8800 - Bid --
- Ask --
- Day's Range
3.8800 - 3.8800 - 52 Week Range
3.3200 - 7.3200 - Volume
254 - Avg. Volume
2,977 - Market Cap (intraday)
127.531M - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.05
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
www.molecularpartners.comRecent News: MOLN
Performance Overview: MOLN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MOLN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MOLN
Valuation Measures
Market Cap
121.01M
Enterprise Value
-79.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.52
Price/Book (mrq)
0.66
Enterprise Value/Revenue
-11.33
Enterprise Value/EBITDA
1.34
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.58%
Return on Equity (ttm)
-30.12%
Revenue (ttm)
7.04M
Net Income Avi to Common (ttm)
-61.98M
Diluted EPS (ttm)
-2.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
186.89M
Total Debt/Equity (mrq)
2.07%
Levered Free Cash Flow (ttm)
-34.2M